Pilot Results on Regulatory-Led RWE Generation
![GMP meets Pharmacovigilance - Live Online Training](files/eca/userImages/training.img/Z-ECA-GMP-meets-Pharmacoviligance.jpg)
Recommendation
Tuesday, 29 October 2024 9 .00 - 17.00 h
GMP / GVP Interfaces and Challenges
Results from a pilot on regulatory-led RWE generation (co-authored by the European Medicines Agency, EMA) have recently been published in the Clinical Pharmacology & Therapeutics journal.
Key Learnings
The review presents the experience resulting from EMA's pilot to generate RWE to support evaluations by EU regulators from September 2021 to February 2023.
The article highlights the following key learnings:
- Studies using Real-World Data (RWD) can complement evidence from clinical trials and fill evidence gaps during different stages of a product's lifecycle.
- The need to access additional fit-for-purpose and representative data, and to explore further means to provide timely evidence that meets regulatory timelines.
- The need for early interactions and close collaboration with study requesters, e.g., from the Agency's scientific Committees, to better understand the research question.
Finally, the review shows the agency's perspective on the way forward to maximize the potential of regulatory-led RWE generation. More information is provided in the article on "Real-World Evidence (RWE) to support EU regulatory decision making: results from a pilot regulatory use cases".
Related GMP News
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment
20.06.2024Glossary of Terms and Definitions for Innovative Clinical Trials
21.05.2024Real-World Evidence: FDA´s Considerations for Non-Interventional Studies
14.05.2024How to Handle and Reserve Samples from BA / BE Studies